LSP’s portfolio company Simplify Medical acquired by NuVasive



Amsterdam, the Netherlands, February 25, 2021 – LSP, a leading European investor in health care, announces that NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, has acquired Simplify Medical, a privately held portfolio company and developer of the Simplify® Cervical Artificial Disc for cervical total disc replacement. NuVasive made an upfront payment to Simplify Medical of $150.0 million at closing, subject to customary purchase price adjustments, and agreed to make additional future payments contingent upon milestones related to regulatory approval and net sales from products incorporating the Simplify Cervical Artificial Disc technology. Simplify Medical was a portfolio company of the LSP 5 Fund and the LSP Health Economics Fund 2.

 

The press release of NuVasive related to this transaction can be found here.

 

About LSP
LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over €2 billion ($2.3 billion) and developed more than 120 companies since it started to invest in 1988. With offices in Amsterdam, Munich and Boston, LSP currently has the possibility to invest from four funds, each having a distinctive investment scope and a dedicated team: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies with a health and economic benefit; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; and LSP Public targets public healthcare companies. Among LSP’s signature deals are argenx, Crucell, KuDOS, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma. In addition, LSP is an active contributor to the life sciences industry through roles as founder and board member of the Oncode Institute, initiator of the Dutch Venture Initiative (DVI), as well as board member of European venture capital associations, technology transfer institutes and government bodies. For more information: lspvc.com.
 
 
Contact:
Fouad Azzam
Partner LSP
 
 
René Kuijten
Managing Partner LSP
 
 
 
« back to overview
Follow us

LSP’s portfolio company Simplify Medical acquired by NuVasive



Amsterdam, the Netherlands, February 25, 2021 – LSP, a leading European investor in health care, announces that NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, has acquired Simplify Medical, a privately held portfolio company and developer of the Simplify® Cervical Artificial Disc for cervical total disc replacement. NuVasive made an upfront payment to Simplify Medical of $150.0 million at closing, subject to customary purchase price adjustments, and agreed to make additional future payments contingent upon milestones related to regulatory approval and net sales from products incorporating the Simplify Cervical Artificial Disc technology. Simplify Medical was a portfolio company of the LSP 5 Fund and the LSP Health Economics Fund 2.

 

The press release of NuVasive related to this transaction can be found here.

 

About LSP
LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over €2 billion ($2.3 billion) and developed more than 120 companies since it started to invest in 1988. With offices in Amsterdam, Munich and Boston, LSP currently has the possibility to invest from four funds, each having a distinctive investment scope and a dedicated team: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies with a health and economic benefit; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; and LSP Public targets public healthcare companies. Among LSP’s signature deals are argenx, Crucell, KuDOS, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma. In addition, LSP is an active contributor to the life sciences industry through roles as founder and board member of the Oncode Institute, initiator of the Dutch Venture Initiative (DVI), as well as board member of European venture capital associations, technology transfer institutes and government bodies. For more information: lspvc.com.
 
 
Contact:
Fouad Azzam
Partner LSP
 
 
René Kuijten
Managing Partner LSP
 
 
 
« back to overview